Berliner Boersenzeitung - Moderna sues Pfizer, BioNTech over Covid vaccine

EUR -
AED 3.873085
AFN 71.98403
ALL 98.091865
AMD 410.865926
ANG 1.906142
AOA 961.670233
ARS 1051.538092
AUD 1.632295
AWG 1.89276
AZN 1.796773
BAM 1.955638
BBD 2.135523
BDT 126.389518
BGN 1.958718
BHD 0.396967
BIF 3123.440963
BMD 1.054463
BND 1.417882
BOB 7.308394
BRL 6.112667
BSD 1.057612
BTN 88.859931
BWP 14.458801
BYN 3.461213
BYR 20667.465977
BZD 2.131923
CAD 1.486845
CDF 3021.035587
CHF 0.936297
CLF 0.037463
CLP 1028.384713
CNY 7.626405
CNH 7.630566
COP 4744.106555
CRC 538.255361
CUC 1.054463
CUP 27.943258
CVE 110.255856
CZK 25.271148
DJF 188.334381
DKK 7.463529
DOP 63.724715
DZD 140.438353
EGP 51.981689
ERN 15.816938
ETB 128.080678
FJD 2.399904
FKP 0.832305
GBP 0.835681
GEL 2.883997
GGP 0.832305
GHS 16.895599
GIP 0.832305
GMD 74.867216
GNF 9114.244125
GTQ 8.168323
GYD 221.171657
HKD 8.209522
HNL 26.709785
HRK 7.521754
HTG 139.038469
HUF 408.314303
IDR 16764.161957
ILS 3.953817
IMP 0.832305
INR 89.078624
IQD 1385.485097
IRR 44384.968904
ISK 145.147177
JEP 0.832305
JMD 167.96607
JOD 0.747724
JPY 162.71943
KES 136.968641
KGS 91.215016
KHR 4272.645655
KMF 491.985906
KPW 949.015895
KRW 1471.950676
KWD 0.32429
KYD 0.881427
KZT 525.596411
LAK 23240.072622
LBP 94711.445261
LKR 308.984375
LRD 194.603861
LSL 19.241504
LTL 3.113554
LVL 0.637834
LYD 5.165572
MAD 10.544126
MDL 19.217406
MGA 4919.592002
MKD 61.604891
MMK 3424.85323
MNT 3583.063688
MOP 8.480797
MRU 42.220499
MUR 49.781576
MVR 16.291845
MWK 1833.947905
MXN 21.453199
MYR 4.713979
MZN 67.384089
NAD 19.241504
NGN 1756.545202
NIO 38.916773
NOK 11.692976
NPR 142.176209
NZD 1.823932
OMR 0.405466
PAB 1.057612
PEN 4.015067
PGK 4.252647
PHP 61.930171
PKR 293.652946
PLN 4.319842
PYG 8252.315608
QAR 3.85558
RON 4.982551
RSD 116.987298
RUB 105.311966
RWF 1452.579533
SAR 3.960703
SBD 8.847383
SCR 14.594154
SDG 634.2631
SEK 11.576527
SGD 1.416885
SHP 0.832305
SLE 23.83472
SLL 22111.557433
SOS 604.449871
SRD 37.238876
STD 21825.245831
SVC 9.254233
SYP 2649.368641
SZL 19.234405
THB 36.739624
TJS 11.274465
TMT 3.701164
TND 3.336823
TOP 2.469661
TRY 36.293586
TTD 7.181404
TWD 34.245573
TZS 2813.266686
UAH 43.686277
UGX 3881.678079
USD 1.054463
UYU 45.386236
UZS 13537.877258
VES 48.222799
VND 26772.804141
VUV 125.187913
WST 2.943628
XAF 655.902604
XAG 0.034867
XAU 0.000411
XCD 2.849738
XDR 0.796734
XOF 655.902604
XPF 119.331742
YER 263.483869
ZAR 18.164652
ZMK 9491.432086
ZMW 29.037592
ZWL 339.536511
  • RBGPF

    61.8400

    61.84

    +100%

  • SCS

    -0.0400

    13.23

    -0.3%

  • BCC

    -0.2600

    140.09

    -0.19%

  • NGG

    0.3800

    62.75

    +0.61%

  • CMSD

    0.0822

    24.44

    +0.34%

  • VOD

    0.0900

    8.77

    +1.03%

  • AZN

    -1.8100

    63.23

    -2.86%

  • BP

    -0.0700

    28.98

    -0.24%

  • CMSC

    0.0200

    24.57

    +0.08%

  • GSK

    -0.6509

    33.35

    -1.95%

  • JRI

    0.0235

    13.1

    +0.18%

  • RIO

    0.5500

    60.98

    +0.9%

  • BCE

    -0.0200

    26.82

    -0.07%

  • BTI

    0.9000

    36.39

    +2.47%

  • RYCEF

    0.0400

    6.82

    +0.59%

  • RELX

    -1.5000

    44.45

    -3.37%

Moderna sues Pfizer, BioNTech over Covid vaccine

Moderna sues Pfizer, BioNTech over Covid vaccine

Moderna said Friday it is suing rival vaccine makers Pfizer and BioNTech, alleging the partners infringed on its patents in developing their Covid-19 shot administered to hundreds of millions around the world.

Text size:

The lawsuits set up a high-stakes showdown between the leading manufacturers of Covid-19 shots that are a key tool in the fight against the disease.

"Moderna believes that Pfizer and BioNTech's Covid-19 vaccine Comirnaty infringes patents Moderna filed between 2010 and 2016 covering Moderna's foundational mRNA technology," the US-based biotech firm said in a statement.

"Pfizer and BioNTech copied this technology, without Moderna's permission, to make Comirnaty," Moderna alleged.

Pfizer and BioNTech said they were aware of the litigation, and each issued statements denying any wrongdoing.

"BioNTech's work is original, and we will vigorously defend against all allegations of patent infringement," the firm said, adding it "respects valid and enforceable intellectual property rights of others."

Pfizer pledged to "vigorously defend against the allegations of the lawsuit."

The mRNA technology used in the Moderna and Pfizer-BioNTech shots differs from that in traditional vaccines, which rely on injecting weakened or dead forms of a virus to allow the immune system to recognize it and build antibodies.

Instead, mRNA vaccines deliver instructions to cells to build a harmless piece of the spike protein found on the surface of the virus that causes Covid-19.

After creating this spike protein, cells can recognize and fight the real virus, hailed as a major advancement in development of vaccines.

- Key tool against deadly pandemic -

The shots have repeatedly been the subject of inaccurate claims that they are dangerous, but health authorities say they are safe and effective.

The lawsuits -- in US district court in Massachusetts, and in regional court in Dusseldorf, Germany -- are not seeking the removal of the rival vaccine or an injunction on future sales.

Moderna said it had begun building up the technology in 2010 and patented work on corona viruses in 2015 and 2016, which allowed for rollout of its shots in "record time" after the pandemic struck.

The virus has killed at least 6.48 million people worldwide since 2020 and made nearly 600 million ill, according to a Johns Hopkins University tracker.

In addition to death and suffering, the disease has led to a re-shaping of life ranging from a change in norms on working from home to a scrambling of supply chains and workforces.

Moderna said it pledged in October 2020 not to enforce its Covid-19-related patents while the pandemic continued, but less than two years later changed that stance as the fight shifted gears.

"Moderna expected companies such as Pfizer and BioNTech to respect its intellectual property rights and would consider a commercially reasonable license should they request one for other markets," it said.

"Pfizer and BioNTech have failed to do so," the firm added.

These types of lawsuits are not unheard of in the pharmaceutical industry, where patents can be worth billions of dollars, and can take years to resolve.

"It is an unfortunate but rather regular occurrence that other companies make allegations that a successful product potentially infringes their intellectual property rights," BioNTech said in a statement.

(K.Müller--BBZ)